Literature DB >> 15721872

Urocortin-induced relaxation in the human internal mammary artery.

Zhi-Wu Chen1, Yu Huang, Qin Yang, Xianwu Li, Wei Wei, Guo-Wei He.   

Abstract

OBJECTIVE: Urocortin, a potent vasodilator, plays physiological or pathophysiological roles in the cardiovascular system. However, little is known about its action in human vascular tissues. The present study was designed to investigate the vascular effect of urocortin on human internal mammary artery (IMA) in vitro and the possible underlying mechanisms.
METHODS: Human IMA was obtained from patients undergoing coronary artery bypass grafting. The isolated IMA rings were mounted in organ baths and changes in isometric tension were measured by using Grass force-displacement transducer. Corticortropin-releasing factor-receptors (CRF-R) were also analyzed in the IMA by using RT-PCR analysis.
RESULTS: In 9,11-dideoxy-11alpha,9alpha-epoxy-methanoprostaglandin F(2alpha) (U46619)-precontracted endothelium-intact rings, urocortin induced concentration-dependent relaxations with pD(2) of 8.69+/-0.11 and this effect was markedly reduced in endothelium-denuded rings. Relaxations to urocortin in endothelium-intact rings were attenuated to the same extent after treatment with N(G)-nitro-l-arginine (l-NNA) and 1H-[1,2,4]oxadizolo[4,3-a]quinoxalin-1-one (ODQ). Urocortin-induced relaxations were also inhibited by treatment with putative K(+) channel blockers, such as tetraethylammonium (TEA(+)), charybdotoxin (CTX), and iberiotoxin (IBX). In endothelium-denuded rings, treatment with TEA(+), CTX, or IBX attenuated relaxation to urocortin as well as sodium nitroprusside (SNP). The bands for CRF-R1, CRF-R2alpha, and CRF-R2beta mRNAs were observed in both endothelium-intact and endothelium-denuded human IMA.
CONCLUSION: Urocortin produced both endothelium-dependent and -independent relaxation in human IMA rings. The endothelium-dependent component primarily involves the release of endothelial nitric oxide (NO) that in turn stimulates Ca(2+)-activated K(+) channels in vascular smooth muscle via cyclic GMP-dependent mechanisms. CRF-R1, CRF-R2alpha, and CRF-R2beta mRNAs are present in the human IMA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15721872     DOI: 10.1016/j.cardiores.2004.11.018

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  9 in total

Review 1.  Drugs' development in acute heart failure: what went wrong?

Authors:  Vincenzo Teneggi; Nithy Sivakumar; Deborah Chen; Alex Matter
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

2.  Arterial grafts: clinical classification and pharmacological management.

Authors:  Guo-Wei He
Journal:  Ann Cardiothorac Surg       Date:  2013-07

3.  Evaluation of Serum Urocortin 2 Levels in Patients with Hypertension.

Authors:  Gamze Aslan; Saide Aytekin
Journal:  High Blood Press Cardiovasc Prev       Date:  2020-01-10

Review 4.  Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: ancient CRF paralogs.

Authors:  Eva M Fekete; Eric P Zorrilla
Journal:  Front Neuroendocrinol       Date:  2006-11-02       Impact factor: 8.606

5.  Urocortin 2 lowers blood pressure and reduces plasma catecholamine levels in mice with hyperadrenergic activity.

Authors:  Yusu Gu; Kuixing Zhang; Nilima Biswas; Ryan S Friese; Dennis H Lin; Sushil K Mahata; Masahiko Hoshijima; Daniel T O'Connor; Kirk L Peterson; Bhawanjit K Brar
Journal:  Endocrinology       Date:  2010-07-28       Impact factor: 4.736

6.  Vasoprotective effects of urocortin 1 against atherosclerosis in vitro and in vivo.

Authors:  Akinori Hasegawa; Kengo Sato; Remina Shirai; Rena Watanabe; Keigo Yamamoto; Kaho Watanabe; Kyoko Nohtomi; Tsutomu Hirano; Takuya Watanabe
Journal:  PLoS One       Date:  2014-12-02       Impact factor: 3.240

7.  Vascular effects of urocortins 2 and 3 in healthy volunteers.

Authors:  Sowmya Venkatasubramanian; Megan E Griffiths; Steven G McLean; Mark R Miller; Rosa Luo; Ninian N Lang; David E Newby
Journal:  J Am Heart Assoc       Date:  2013-01-31       Impact factor: 5.501

8.  Suxiao jiuxin pill induces potent relaxation and inhibition on contraction in human artery and the mechanism.

Authors:  Xiao-Yan Bai; Ping Zhang; Qin Yang; Xiao-Cheng Liu; Jun Wang; Yong-Ling Tong; Song-Jin Xiong; Li-Hua Liu; Lei Wang; Guo-Wei He
Journal:  Evid Based Complement Alternat Med       Date:  2014-04-07       Impact factor: 2.629

9.  Activation of PERK branch of ER stress mediates homocysteine-induced BKCa channel dysfunction in coronary artery via FoxO3a-dependent regulation of atrogin-1.

Authors:  Wen-Tao Sun; Xiang-Chong Wang; Shiu-Kwong Mak; Guo-Wei He; Xiao-Cheng Liu; Malcolm John Underwood; Qin Yang
Journal:  Oncotarget       Date:  2017-05-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.